| Budget Amount *help |
¥5,200,000 (Direct Cost: ¥4,000,000、Indirect Cost: ¥1,200,000)
Fiscal Year 2016: ¥1,690,000 (Direct Cost: ¥1,300,000、Indirect Cost: ¥390,000)
Fiscal Year 2015: ¥2,080,000 (Direct Cost: ¥1,600,000、Indirect Cost: ¥480,000)
Fiscal Year 2014: ¥1,430,000 (Direct Cost: ¥1,100,000、Indirect Cost: ¥330,000)
|
|---|
| Outline of Final Research Achievements |
Prostate cancer has been increasing and has become a major cancer in Japan. Prostate cancer contains highly -tumorigenic ‘cancer stem cells’, which are involved in therapy resistance. So far, however, therapeutic agents targeting the prostate cancer stem cells are not fully identified. In this study, we identified TRIB1 as a novel survival factor for prostate cancer stem cells. TRIB1 supports prostate cancer cell growth via the function of the ER stress protein, GRP78. We also found a candidate compound that suppresses TRIB1-mediated survival signaling. Our findings would be a basis for the development of new therapeutic strategy for complete cure of prostate cancer.
|
